The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse danicopan (Voydeya®) through the basic healthcare package. This medicine can be used for certain patients with paroxysmal nocturnal haemoglobinuria (PNH). PNH is a rare bone marrow condition. By now the minister has adopted our advice and included danicopan (Voydeya®) in the Medicine Reimbursement System (GVS). This means that the medicinal product will be reimbursed from the healthcare insurer's basic healthcare package for certain patients. The reimbursement starts on 1 January 2026. There are additional conditions for reimbursement.
Danicopan is intended for certain people with paroxysmal nocturnal haemoglobinuria
Danicopan is the active substance; the brand name is Voydeya®. The medicine is a capsule that is swallowed.
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, non-hereditary bone marrow condition. Patients with PNH suffer from severe anaemia. Anaemia is caused by the increased breakdown of red blood cells, infections that cause the breakdown of white blood cells, and thrombosis.
Danicopan can be used in combination with a C5 inhibitor for treating adult patients with PNH:
- who are still suffering from anaemia
- caused by the breakdown of red blood cells outside the blood vessels (referred to as extravascular haemolysis, EHV), and
- after treatment with a C5 inhibitor or C3 inhibitor.
These patients have noticeable complaints such as fatigue, jaundice or anaemia. These are also referred to as clinically significant symptoms; they arise from excessively rapid breakdown of red blood cells outside the blood vessels, for instance in the spleen or liver.
Advice from the National Health Care Institute on reimbursing danicopan
The National Health Care Institute advises the Minister of VWS to reimburse danicopan (Voydeya®) through the basic healthcare package. The recommendation is that the medicinal product should be included in Annex 1A of the GVS, in a newly-formed cluster together with iptacopan (Fabhalta®). Specific additional conditions, known as Annex 2 conditions, apply for Voydeya®.
The National Health Care Institute advised you on 18 March 2025 to include iptacopan in the GVS. At present, iptacopan is not reimbursed. Should iptacopan not get included in the GVS, danicopan can be placed on Annex 1B.
For more information on the GVS and the Annexes 1A, 1B and 2, see page ‘Reimbursement of outpatient medicines‘.
Conditions for reimbursing danicopan
Only for an insured person with paroxysmal nocturnal haemoglobinuria who, after treatment for at least 3 months with a C5 inhibitor, is anaemic with a haemoglobin value of <6.5 mmol/l.
More information or questions?
If you have any questions about this advice, please send your question to the National Health Care Institute via warcg@zinl.nl. If you have questions about the reimbursement of a medicinal product, the personal expenses or whether you should pay a contribution, please ask your health insurance provider.
How did the advice come about?
The Scientific Advisory Board (WAR) advises the National Health Care Institute about the assessment. The Minister makes the final decision whether or not to reimburse the medicinal product from the basic healthcare package.
Explanation about the reimbursement of medicinal products
Danicopan is an extramural medicinal product. ‘Extramural’ means medicines for home use that can be obtained at a pharmacy with a prescription from a physician. They are only reimbursed from the basic healthcare package if they are listed in the GVS.